Massachusetts-based AI biotechnology company Nimbus Therapeutics and drug discovery company Anagenex have entered a research partnership to discover small-molecule drugs for various complex targets.
As part of the agreement, Anagenex will receive an upfront payment (amount undisclosed) and potential milestone payments. It will also be eligible for an option from Nimbus for each program in the collaboration.
The collaboration will leverage Anagenex's AI-driven parallel biochemistry platform to generate a vast amount of data points for each of Nimbus' nominated targets. The generated data will then be used to train Anagenex’s AI models to design target-specific compounds, potentially identifying potent candidates for new medicines.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.